Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.
2.
3.

Chop-lump tests for vaccine trials.

Follmann D, Fay MP, Proschan M.

Biometrics. 2009 Sep;65(3):885-93. doi: 10.1111/j.1541-0420.2008.01131.x. Epub 2009 Feb 5.

PMID:
19210727
4.

Design and estimation for evaluating principal surrogate markers in vaccine trials.

Huang Y, Gilbert PB, Wolfson J.

Biometrics. 2013 Jun;69(2):301-9. doi: 10.1111/biom.12014. Epub 2013 Feb 14.

5.

Mark-specific hazard ratio model with multivariate continuous marks: an application to vaccine efficacy.

Juraska M, Gilbert PB.

Biometrics. 2013 Jun;69(2):328-37. doi: 10.1111/biom.12016. Epub 2013 Feb 19.

6.

Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials.

Gilbert PB, Bosch RJ, Hudgens MG.

Biometrics. 2003 Sep;59(3):531-41.

PMID:
14601754
7.
9.

Use of placebos in Phase 1 preventive HIV vaccine clinical trials.

Huang Y, Karuna ST, Janes H, Frahm N, Nason M, Edlefsen PT, Kublin JG, Corey L, McElrath MJ, Gilbert PB.

Vaccine. 2015 Feb 4;33(6):749-52. doi: 10.1016/j.vaccine.2014.10.017. Epub 2014 Oct 23.

11.

Statistical issues in the design of HIV vaccine trials.

Schaper C, Fleming TR, Self SG, Rida WN.

Annu Rev Public Health. 1995;16:1-22. Review.

PMID:
7639865
12.

Incorporating founder virus information in vaccine field trials.

Follmann D, Huang CY.

Biometrics. 2015 Jun;71(2):386-96. doi: 10.1111/biom.12277. Epub 2015 Mar 13.

13.

Semiparametric methods for multiple exposure mismeasurement and a bivariate outcome in HIV vaccine trials.

Golm GT, Halloran ME, Longini IM Jr.

Biometrics. 1999 Mar;55(1):94-101.

PMID:
11318183
14.

[HIV/AIDS vaccines: heading for new vaccine approaches?].

Girard MP.

Bull Soc Pathol Exot. 2008 Jun;101(3):220-6. French.

PMID:
18681215
15.

Sieve analysis in HIV-1 vaccine efficacy trials.

Edlefsen PT, Gilbert PB, Rolland M.

Curr Opin HIV AIDS. 2013 Sep;8(5):432-6. doi: 10.1097/COH.0b013e328362db2b. Review.

16.
17.
19.

Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines.

Longini IM Jr, Datta S, Halloran ME.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Dec 15;13(5):440-7.

PMID:
8970471
20.

HIV-1 vaccines and adaptive trial designs.

Corey L, Nabel GJ, Dieffenbach C, Gilbert P, Haynes BF, Johnston M, Kublin J, Lane HC, Pantaleo G, Picker LJ, Fauci AS.

Sci Transl Med. 2011 Apr 20;3(79):79ps13. doi: 10.1126/scitranslmed.3001863.

Supplemental Content

Support Center